Skip to main content
OpenTrials
Completed

NCT Number: NCT00952588

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

The purpose of this study is to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Research Site, Westmead, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of written informed consent
  • Newly diagnosed male or female patients aged 60 and over
  • De Novo or Secondary AML
  • Not eligible for intensive induction with anthracycline-based combination chemotherapy as a result of at least one of the following:Age ≥75 years; Adverse cytogenetics, e.g., as defined by the MRC Prognostic Groupings; WHO performance status >2; Organ dysfunction arising from significant co-morbidities not directly linked to leukaemia

Exclusion criteria

  • Participation in another clinical study in which an investigational product was received within 14 days before the first dose in this study, or at any time if the patient has not recovered from side-effects associated with that investigational product
  • Administration of LDAC is clinically contraindicated
  • Patients with AML of FAB M3 classification Acute Promyelocytic Leukaemia (APL)
  • Patients with blast crisis of chronic myeloid leukaemia

Treatment and study plan

AZD1152

Drug

1200 mg, iv, 7 day infusion

LDAC

Drug

20 mg, sc, bd, 10 days

Primary outcomes

  1. Percentage of Patients With Overall Complete Response for Stage I

    Time frame: IWG Cheson criteria every 28 days from randomization for study duration (24 months, between 2009 - 2011)

    Percentage of patients achieving either a complete response (CR) or a confirmed complete remission with incomplete recovery of neutrophils or platelets (confirmed CRi). Per Cheson Criteria: Confirmed complete remission (CRi) is defined as a disappearance of blasts in the peripheral blood; a decrease in bone marrow blasts to <5% total bone marrow nucleated cells demonstrated in bone marrow aspirate; absence of Auer rods; no persistent extramedullary leukaemia. Complete response (CR) is defined as all requirements to meet CRi and in addition: recovery of neutrophils to ≥1.0 x 109/L and platelets to ≥100 x 109/L; transfusion-independence.

Secondary outcomes

  1. Duration of Response (DoR): Stage I and Transition Phase

    Time frame: DoR was measured every 28 days from randomization for study duration (24 months, between 2009 - 2011)

    DoR was defined for the median of days which showed a confirmed CRi or CR, as the time from first documented evidence of CRi or CR until the first documented sign of disease progression or death. Duration of Response was measured from the Response Start date until evidence of patient relapse or death. Stage I : 45 patients randomized in a 2:1 ratio to AZD1152 or LDAC. Transition phase: enrollment of up to 30 additional patients randomized as per stage I.

  2. Disease Free Survival (DFS)

    Time frame: DFS was measured every 28 days from randomization for study duration (24 months, between 2009 - 2011)

    Disease-free Survival is defined as the time from randomisation to relapse or death from any cause.

  3. Time To Complete Response (TTCR)

    Time frame: Response was measured every 28 days from randomization for study duration (24 months, between 2009 - 2011)

    TTCR is measured as time from randomization to either a complete response (CR) or a confirmed complete remission with incomplete recovery of neutrophils or platelets (confirmed CRi)

  4. Overall Survival (OS)

    Time frame: Assessed from randomisation until the date of death from any cause, assessed up to 24 months

    Overall Survival is defined as the median time from randomisation to death from any cause. Patients who were not known to have died at the time of the analysis were censored at the date they were last known to be alive.

  5. Percent of Patients With Worsened Trial Outcome Index (TOI)

    Time frame: TOI was measured every 28 days from randomization for study duration (24 months, between 2009 - 2011)

    TOI is derived from the sum of the Functional Well Being (FWB), Physical Well Being (PWB) and additional subscales of the FACT-Leu. The TOI subscale consists of 31 items with TOI scores ranging from 0 to 124. The TOI is described as a summary measure of HRQoL. Higher scores indicate better HRQoL. Negative changes from baseline indicate a worsening of HRQoL while positive changes indicate an improvement in HRQoL. A response of "Worsened" was a change from baseline in score of less than or equal to -9.

  6. Percent of Patients With Worsened Functional Assessment of Cancer Therapy - Leukaemia (FACT-Leu) Score.

    Time frame: FACT-Leu was measured every 28 days from randomization for study duration (24 months, between 2009 - 2011)

    The total FACT-Leu score consists of 44 items with total scores ranging from 0 to 176. Higher scores indicate better HRQoL. Negative changes from baseline indicate a worsening of HRQoL while positive changes indicate an improvement in HRQoL. A response of "Worsened" was a change from baseline in score of less than or equal to -11.

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged ≥ 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)

Acronym: SPARK-AML1

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
Aug 6, 2009
Registry last updated
Feb 24, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.